Comparative Pharmacology
Head-to-head clinical analysis: SELSUN versus VITUZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELSUN versus VITUZ.
SELSUN vs VITUZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selenium sulfide is an antifungal agent that inhibits the growth of Malassezia species by reducing selenium to elemental selenium, which is toxic to the fungus. It also reduces sebum production via unknown mechanisms.
Vituz is an epidermal growth factor receptor (EGFR) inhibitor that binds to the tyrosine kinase domain, blocking downstream signaling pathways involved in cell proliferation and survival.
Apply 5-10 mL of 2.5% selenium sulfide lotion to affected areas of scalp, lather with water, leave on for 2-3 minutes, then rinse thoroughly. Use twice weekly for 2 weeks, then once weekly for maintenance.
400 mg orally every 8 hours for 5 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Not well defined due to minimal systemic absorption; topical application yields negligible plasma levels.
The terminal elimination half-life is 12-15 hours in patients with normal renal function, allowing twice-daily dosing. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to 20-28 hours; in severe impairment (CrCl <30 mL/min), it exceeds 40 hours.
Selenium sulfide is minimally absorbed; absorbed portions are excreted renally (approx. 80-90%) and fecally (10-20%).
VITUZ (vitluzolamide) is primarily excreted via renal elimination as unchanged drug (45-55%) and as the major inactive metabolite M1 (20-30%). Biliary/fecal excretion accounts for 15-20%, primarily as M1. Less than 5% is eliminated via other routes.
Category C
Category C
Antifungal/Antiseborrheic
Antifungal